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isease is described in the CAT scan of the case. Treatment
cluded transplantectomy and wide-spectrum antibiotics.
here was histological evidence of injuries consistent with
N in the patient. Two microorganisms commonly reported
 be isolated in the literature, K. pneumoniae and K. oxytoca,
ere found in cultures of the pathological specimen of this
se.6
Companion diagnostics must be made with the presence
f renal abscesses, xanthogranulomatous pyelonephritis, and
nal tuberculosis.7
Even though our patient was not diabetic, the history of
munosuppression due to multiple previous renal trans-
lants may become a risk factor associated with EPN.
This kind of clinical cases should be reported to further
vestigate their epidemiology and clarify the pathogenic
pects guiding the selection of optimal treatment for future
ses.6–9
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upus  anticoagulant-hypoproth
 rare  association  in systemic  
índrome  de  anticoagulante  lúpico
na  extran˜a asociación  en  el  lupus the Editor,
pus anticoagulant-hypoprothrombinaemia syndrome
AHS) is a disorder characterised by the acquired deﬁcit of
agulation factor II (prothrombin) together with the pres-
ce of lupus anticoagulant. It is an extremely rare syndrome
ess than 100 cases described in the literature),1 in which
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ere is a predisposition to bleeding, unlike antiphospholipid
ndrome (APS), which is characterised by an increased risk
f thrombosis.
The ﬁrst case was described by Rapaport et al.2 in 1960, but
 was not until more  than 20 years later that the study be Bajaj
 al.3 demonstrated the presence of anti-prothrombin anti-
odies. Although these antibodies do not impede prothrombin
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activity, they lead to secondary hypoprothrombinaemia due to
rapid clearance of the antigen–antibody complexes from the
circulation.
The most common treatment of LAHS consists of steroid
therapy together with other immunosuppressors (cyclophos-
phamide, azathioprine, or rituximab). The aim of treatment
if to reduce the risk of bleeding and eliminate prothrombin
inhibitor.4
We  present the clinical case of a 37-year-old Bulgarian man,
with a history of lupus nephropathy diagnosed in his country
in 2004. Despite receiving treatment, he had a poor clini-
cal course, requiring renal replacement therapy 7 years after
diagnosis. Two years later, he attended our hospital to con-
tinue haemodialysis. He was assessed by the rheumatology
team and the haematology team for chronic thrombocyto-
penia, for which he received immunosuppressive treatment
with steroids, immunoglobulins, and rituximab, as well as
thrombopoietin-receptor agonists (eltrombopag), with a poor
response. He also had APS and was positive for anti-cardiolipin
antibodies and anti-2-microglobulin antibodies. This pre-
sented with several thrombotic events (thrombosis of several
vascular access devices) and a cerebrovascular event in 2014,
for which he had been started on anticoagulant treatment.
The patient was admitted to our department for an episode
of general malaise and low-grade fever in the context of
a possible central venous catheter bacteraemia. He started
broad-spectrum antibiotic treatment with a clear clinical
improvement, and it was decided to stop anticoagulation
temporarily to allow a change of venous catheter. During
this period of withheld anticoagulation, he experienced a
transient ischaemic attack which presented as right-sided
paraesthesia and reduced power, with expressive aphasia. It
was therefore decided to re-start anticoagulation with heparin
sodium. Surprisingly, brain magnetic resonance angiography
showed, along with old ischaemic lesions, a signiﬁcant sub-
Table 1 – Clotting factor activity with and without
correction for lupus anticoagulant.
Factor Factor
activity (%)
Corrected factor
activity
(SynthAFax®) (%)
Mixed factor
activity (%)
Factor II 25 – 70
Factor V 102 – –
Factor VII 136 – –
Factor X 114 – –
Factor VIII 16 83 –
Factor IX 6 96 –
Factor XI 8 94 –
Factor XII 7 98 –
dural haematoma at the left cerebral convexity with mas
effect in the parieto-occipital region (Fig. 1). Between the
neurosurgery and neurology teams, it was decided to stop
anticoagulation and wait and see how he progressed clini
cally and radiologically. Given the presence of thrombotic and
haemorrhagic events, a new coagulation study was requested
This showed lupus anticoagulant, elevated levels of anti
cardiolipin antibodies and anti-2-microglobulin antibodies
and low coagulation factor II (prothrombin) activity, which
corrected with mixing, conﬁrming the presence of lupu
anticoagulant-hypoprothrombinaemia syndrome (Table 1).
Combined treatment was started with anticoagulation and
immunosuppression with low dose steroids, mycophenolic
acid, and rituximab 6-monthly.
The association of lupus anticoagulant with hypopro
thrombinaemia is a rare syndrome, infrequently described
It is a syndrome that is more  common in children and young
adults, and is commonly associated with viral infections and
auto-immune diseases (above all systemic lupus erythemato
sus), although cases have also been described in association
with drugs or tumours.1 LAHS is usually self-limiting when
associated with viral infection, whereas in those associated
with auto-immune diseases, relapse is common despite
treatment.
It is clinically characterised by haemorrhagic diathesis
with epistaxes and ecchymoses being the most common
types of bleed, although cases have been described o
haematuria, gastrointestinal bleeding, and intracranial hae
morrhage, amongst others5 Several cases have been described
of LAHS with associated thrombosis, in some cases multiple
thromboses. However, those cases were mainly in the contex
of starting treatment against prothrombin inhibitor.
Treatment of LAHS is based on immunosuppression to
avoid haemorrhagic events and to try to eliminate facto
II-inhibitor.4 An increase in thrombotic events has been
described in patients with LAHS, as immunosuppression
reduces inhibitor levels, but not lupus anticoagulant levels.
There are no guidelines indicating what the best treatmen
is for LAHS, most treatment being based on corticoids with
another immunosuppressor.
In conclusion, in patients with lupus nephropathy
with both thrombotic and haemorrhagic processes, lupuFig. 1 – Magnetic resonance-angiography image of
ischaemic lesions (frontal atrophy, arrow) and haemorrhage
(left parieto-occipital region, arrow).anticoagulant-hypoprothrombinaemia syndrome must be
suspected. Diagnosis and treatment-based on immunosup-
pression to control the clinical manifestations of the disease
are essential.
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history included familial hypoparathyroidism in chronic
treatment with vitamin D and calcium carbonate, bilateral
sensorineural deafness and left kidney agenesis. With this his-
tory, in 2007, she was diagnosed with HDR syndrome. A genetic
study demonstrated the presence of the c.431 mutation in the
GATA3 gene (gene for the transcription factor GATA3, located
in the short arm of chromosome 10). Both the patient and her
mother were heterozygous for this mutation. The rest of the
family (father, sister and maternal aunt) did not have any clini-
cal manifestations of the syndrome; nevertheless, a molecular
genetic study ruled out the presence of this mutation. Prior
to pregnancy, the patient had been examined in the urology
department as she was a single-kidney patient. She had
undergone laboratory testing that showed mild kidney failure
with a serum Cr of 1.3 mg/dl and proteinuria at 2.8 g/day.
Since she did not have HTN, the presence of pre-eclampsia
was ruled out, and she was diagnosed with worsening of renal
function in a patient with chronic kidney disease (CKD) in
pregnancy.88  n e f r o l o g i a. 2 0
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arakat  syndrome  or HDR  synd
f kidney  disease  and  deafnes
índrome  hipoparathyroidism,  dea
índrome  de  Barakat  otra  asociació
ear Editor,
 a patient has kidney disease and deafness, we think on
lport syndrome, a widespread entity. However, this is not
ways the case. One of the recent issues of the journal
efrología included an excellent review of kidney disease in
e context of mitochondrial diseases and how nephrologists
ould suspect this diseases in a nephropathy (tubulopathy or
omerular injury, manifested by kidney failure and protein-
ria) which is accompanied by hearing loss or sensorineural
eafness.1 In this letter, we present a case of Barakat syn-
rome or hypoparathyroidism, deafness and renal dysplasia
DR) syndrome, another disease that should be included in
e differential diagnosis of kidney disease and hereditary
eafness.2,3
A 32-year-old patient was admitted to the obstetrics
epartment owing to oedema. She was 36 weeks pregnant and
e laboratory tests revealed a plasma creatinine at 1.4 mg/dl
d 6 grams of proteinuria in a 24-h urine collection. MedicalPlease cite this article as: Rodríguez Benítez P, Jaldo Rodríguez MT, Hernández Coronado A, Torres Aguilera E, Melero R, Tejedor A.
ndrome hipoparathyroidism, deafness and renal displasia o síndrome de Barakat otra asociación de sordera y nefropatía. Nefrologia.
16;36:188–189.
